A recent study evaluated the effects of smoking and other environmental factors on joint inflammation in patients at risk of developing rheumatoid arthritis.
A pooled analysis of the phase 3 BOREAS and NOTUS trials evaluated whether add-on dupilumab, given on top of triple inhaler therapy, improves health-related quality of life and respiratory symptoms in...
A phase 2 trial evaluated whether benralizumab, with or without prednisolone, could improve clinical and symptom outcomes for adults presenting with eosinophilic exacerbations of asthma or chronic...
From inhaler selection to follow-up frequency and vaping risks, here are concise, evidence-based answers to the questions primary care clinicians ask most about managing COPD. These FAQs address the best...
The US Preventive Services Task Force has updated their 2009 guidelines on smoking cessation interventions and further examined the effectiveness of electronic nicotine delivery systems.
The FDA has approved a drug already indicated for COPD treatment for the long-term, once-daily maintenance of asthma in individuals 12 years old and older.
